Breaking Finance News

Johnson & Johnson (NYSE:JNJ) target price raised to $123.13, issued a report today by Vetr Inc.

Yesterday Johnson & Johnson (NYSE:JNJ) traded -0.54% lower at $118.91. The company’s 50-day moving average is $119.99 and its 200-day moving average is $116.25. The last closing price is up 2.20% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 4,772,980 shares of Johnson & Johnson exchanged hands, down from an avg. volume of 6,639,800

Johnson & Johnson (NYSE:JNJ) had its target price raised to $123.13 by Vetr Inc. in a report released 9/21/2016. The new target price indicates a possible upside of 0.04% based on the company's last closing price.

Performance Chart

Johnson & Johnson (NYSE:JNJ)

With a total market value of $0, Johnson & Johnson has price-earnings ratio of 22.14 with a one year low of $89.90 and a one year high of $126.07 .

A total of 18 equity analysts have released a research note on JNJ. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $117.44.

Brief Synopsis About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.